🔗 Share this article

While the United States continues making unprecedented adjustments to its immunization schedules, one figure has surfaced unexpectedly: Dr. Tracy Beth Høeg, a US-based sports medicine doctor and public health researcher who initially gained attention by casting doubt on Covid vaccinations in the pandemic and has zeroed in on potential fatalities after COVID-19 vaccination in her short tenure at the Food and Drug Administration.

Scheduled Overhauls to Childhood Vaccine Program

Agency leaders were set to reveal radical changes to the childhood vaccine schedule in December, bringing the US with the Danish vaccine program, it is understood – a substantial departure that would put the US out of step with much of the world with no evidence for public health gain. The announcement has been pushed back until the next year.

Rather than the top vaccines chief, Tracy Beth Høeg is set to speak at the event. She was just designated acting director of the FDA’s drug evaluation center, the fifth person to head the office this year.

Consolidating Power at the FDA

The acting appointment could signify a tighter collaboration between the drug and vaccine branches as Høeg and Dr. Prasad consolidate power at the agency – and it points to a renewed priority upon rolling back already-approved immunizations at the FDA.

The new acting director has frequently advocated for discontinuing some childhood vaccine recommendations in the US to become more similar to Denmark's approach, a country with comprehensive healthcare and a population approximately the population of Wisconsin’s.

To date statements, she has kept her attention on immunizations – traditionally the responsibility of Dr. Prasad, chief of the FDA’s vaccine center – as opposed to pharmaceutical oversight.

Concerns Over Qualifications

Dr. Høeg has no apparent experience in pharmaceutical research, approval processes or management, which has been customary for previous leaders of the biologics center. She has worked at the FDA as a senior adviser to the commissioner and CBER since spring.

“It seems she lacks to have any of the qualifications” for overseeing the CDER, stated a neurologist and psychiatrist. “She lacks experience running a randomized controlled trial. She lacks experience in leading a sizeable institution. She has no expertise in industry regulation.”

Past directors of CBER would “understand legal statutes and the science of drug development”, said Janet Woodcock. “Objectively, she doesn’t have the sort of resume that former directors who led CBER have had.”

This division has an enormous range of responsibilities at the agency, Woodcock emphasized.

“Many people just zeroes in on the novel medication approvals, but the off-patent medication office approves a multitude of off-brand pharmaceuticals. There is also a biologic copycat branch, over-the-counter program and other areas, and all of those have to be managed,” she noted. “The thing you neglect, that is the part that I always told people is going to cause problems.”

Additionally, a significant administrative element to the role, which oversees more than 5,000 employees. “It’s a huge administrative position, if you execute it properly,” Woodcock concluded.

Official Statement and Controversial Initiatives

In response to inquiries about Høeg’s qualifications and whether this appointment indicates more teamwork among agency officials on vaccines, a press secretary stated that the “inquiries rely on incorrect presumptions”.

“This background is consistent with the functions of her role,” the spokesperson explained, pointing to the period Dr. Høeg spent counseling the agency head on “pharmaceutical safety and approval science, including computerized risk analysis and vaccine surveillance”.

As acting director, Høeg inherits the commissioner’s recently launched fast-track approval initiative, a disputed expedited drug-approval program that apparently worried her preceding directors. “How are these medications being picked for this fast-track system? Who takes the calls?” Howard questioned. “There is a lot of lack of transparency happening at the FDA right now.”

Overall, he said, “the agency appears to be shifting towards more relaxed rules of all drugs, except for shots.”

Public Past Work on Immunizations

With immunizations, Dr. Høeg has a more documented, if problematic, history, some experts said. She released a research paper using unverified public submissions to estimate the rate of myocarditis following COVID-19 immunization. She advised the Florida top health official Joseph Ladapo, who reportedly have modified findings to imply Covid vaccinations are more dangerous than they are.

Among her “wish list” for the current administration encompassed altering regulations for new vaccines and halting “unnecessary” vaccines, she remarked post-election on a online show. At the agency, Dr. Høeg has allegedly floated the idea of preventing teenage boys from receiving Covid vaccinations.

“She is an complete ideologue who commences with her beliefs and works backwards to accommodate the evidence in a highly deceptive, dishonest way,” Howard said.

Taking Control and a “Campaign of Retribution”

Høeg joined fellow contrarians, {like|